Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10840MR)

This product GTTS-WQ10840MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10840MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5964MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ1302MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ3965MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ15682MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ10832MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ10985MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ9976MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ2697MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 785
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW